Michael Dockal

USPTO Granted Patents = 31 (Patent Applications = 16)

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 17 (Patent Applications = 20)

Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 73(Granted Patents)

Company Filing History:

Baxter International Inc.

Takeda Pharmaceutical Company Limited

patents

where one patent can have more than one assignee

Years Active: 2011-2023

Loading Chart...

31 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11793855 - TFPI inhibitors and methods of use (2023-10-24),

2. 11160850 - Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders (2021-11-02),

3. 11001613 - TFPI inhibitors and methods of use (2021-05-11),

4. 10822376 - Biologically active peptides (2020-11-03),

5. 10800816 - TFPI inhibitors and methods of use (2020-10-13),

6. 10287319 - Biologically active peptides (2019-05-14),

7. 10201586 - TFPI inhibitors and methods of use (2019-02-12),

8. 10124033 - Peptides and methods of use (2018-11-13),

9. 10036002 - Factor X activation (2018-07-31),

10. 9873892 - Production of fully processed and functional factor X in a furin-secreting mammalian expression system (2018-01-23),

11. 9873720 - TFPI inhibitors and methods of use (2018-01-23),

12. 9777051 - TFPI inhibitors and methods of use (2017-10-03),

13. 9598464 - Biologically active peptides (2017-03-21),

14. 9566364 - Preparations based on fibrinogen and sulfated polysaccharides (2017-02-14),

15. 9556230 - TFPI inhibitors and methods of use (2017-01-31),

Title: The Innovations and Contributions of Michael Dockal

Introduction: Michael Dockal, an accomplished inventor based in Vienna, Austria, has made significant contributions to the field of biomedical research. With a remarkable portfolio of 31 patents to his name, Dockal's innovations are primarily focused on enhancing blood coagulation and treating bleeding disorders. His work has critical implications for patients suffering from coagulation deficiencies.

Latest Patents: Among Dockal's latest patents, the invention related to TFPI inhibitors stands out. This invention provides peptides that bind to Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides and compositions thereof. These peptides can be instrumental in inhibiting TFPI, enhancing thrombin formation in clotting factor-deficient subjects, increasing blood clot formation, treating blood coagulation disorders, purifying TFPI, and identifying TFPI-binding compounds. Another notable patent involves compositions of human prothrombin and activated factor X, which are disclosed for improving hemostasis in the treatment of bleeding disorders and reversing anticoagulant activity. This patent describes effective ratios of prothrombin (FII) and activated factor X (FXa) that are as efficacious as FEIBA®, requiring a lower concentration of FII.

Career Highlights: Michael Dockal has had a distinguished career in the biotechnology sector, working with notable companies including Baxalta GmbH and Baxter International Inc. His experience in these organizations has contributed to the development of innovative therapeutic methods and medical advancements.

Collaborations: Throughout his career, Dockal has collaborated with esteemed colleagues, including Friedrich Scheiflinger and Thomas Polakowski. These collaborations have fostered a productive environment for innovative research and have resulted in transformative biomedical solutions.

Conclusion: Michael Dockal's exemplary work in the field of blood coagulation has not only resulted in valuable patents but also positioned him as a pivotal figure in advancing treatments for bleeding disorders. His innovative approach and collaborations continue to make significant impacts in biomedical research and healthcare.

This text is generated by artificial intelligence and may not be accurate.